Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (<scp>MUK</scp> six open label, multi‐centre phase I/<scp>II</scp> Clinical Trial)
Rakesh Popat(University College London Hospitals NHS Foundation Trust), Jamie Cavenagh(St Bartholomew's Hospital), Gordon Cook(University of Leeds), Matthew Streetly(St Thomas' Hospital), Bhuvan Kishore(National Health Service), Kwee Yong(CRUK Lung Cancer Centre of Excellence), Walter M. Gregory(University of Leeds), Andrew Hall(University of Leeds), Heather Oakervee(Barts Health NHS Trust), Eric Low(Myeloma UK), Sarah Brown(University of Leeds), Louise Flanagan(University of Leeds)
Cited by 8
Related Papers
Guidelines for the diagnosis and management of adult aplastic anaemia
|British Journal of Haematology|2015|750
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
|The Lancet|2010|571
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564